zsp1601
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2018 (NCT03392779)
Timeline
Indications
Studied for
Mechanism of action
- Phosphodiesterase 2AINHIBITOR
PDE2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05692492 | Phase 2 | Jun 3, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT04140123 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2019 | Guangdong Raynovent Biotech Co., Ltd |
| NCT03392779 | Phase 1 | Jan 5, 2018 | Guangdong Zhongsheng Pharmaceutical Co., Ltd., Jilin University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangdong Raynovent Biotech Co., Ltd | For profit | 2 | 2 | 1 | 2019 |
| Guangdong Zhongsheng Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2018 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1